RECURRENT WHO GRADE 2 GLIOMA
Clinical trials for RECURRENT WHO GRADE 2 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE 2 GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE 2 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with brain cancer: drug combo targets recurrent tumors
Disease control OngoingThis study tests whether adding vinblastine to selumetinib works better than selumetinib alone for children and young adults (ages 2-25) with a type of brain tumor called low-grade glioma that has returned or not responded to treatment. Selumetinib blocks a protein that helps tum…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Targeted drug tipifarnib tested in kids with rare HRAS-Driven cancers
Disease control OngoingThis study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…
Matched conditions: RECURRENT WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC